PRLD Prelude Therapeutics Inc
Nasdaq · SEC CIK 1678660 · EDGAR
- Bought, last 12 months
- $25.00M 2 purchases by 2 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 125 since 2021-07-08, latest 2026-06-10 16:44
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Bonita David P | Dir, 10% | $12.50M | — |
| ORBIMED ADVISORS LLC | Dir, 10% | $12.50M | — |
| Huang Jane | Pres, CMO | — | — |
| RA CAPITAL MANAGEMENT, L.P. | 10% | — | — |
Transactions 71
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-04-28 17:14 | 2026-04-27 | PRLD | RA CAPITAL MANAGEMENT, L.P. | 10% | J - Other | — | -1.41M | 6.48M | -18% | — |
| MI | 2026-04-23 18:50 | 2026-04-21 | PRLD | Bonita David P | Dir, 10% | P - Purchase | $4.44 | +2.82M | 1.13M | New | +$12.50M |
| MI | 2026-04-23 18:48 | 2026-04-21 | PRLD | ORBIMED ADVISORS LLC | Dir, 10% | P - Purchase | $4.44 | +2.82M | 1.13M | New | +$12.50M |
| D | 2025-10-07 | 2025-10-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 90.3K | +12% | — |
| D | 2025-10-07 | 2025-10-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $1.47 | -3,355 | 86.9K | -4% | -$4,932 |
| D | 2025-07-08 | 2025-07-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 84.3K | +13% | — |
| D | 2025-07-08 | 2025-07-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $0.79 | -3,355 | 80.9K | -4% | -$2,650 |
| D | 2025-04-07 | 2025-04-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $0.68 | -3,355 | 74.9K | -4% | -$2,281 |
| D | 2025-04-07 | 2025-04-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 78.2K | +14% | — |
| 2025-03-27 | 2025-03-25 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.69 | +675.0K | 2.00M | +51% | +$465.7K | |
| 2025-03-27 | 2025-03-25 | PRLD | Combs Andrew | Chief Chemistry Off | P - Purchase | $0.69 | +100.0K | 480.1K | +26% | +$69.0K | |
| M | 2025-03-24 | 2025-03-20+ | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.73 | +20.4K | 1.32M | +2% | +$14.9K |
| M | 2025-03-18 | 2025-03-14+ | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.75 | +39.1K | 1.29M | +3% | +$29.3K |
| M | 2025-03-14 | 2025-03-12+ | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.7151 | +97.5K | 1.26M | +8% | +$69.7K |
| D | 2025-01-07 | 2025-01-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 72.7K | +15% | — |
| D | 2025-01-07 | 2025-01-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $1.39 | -3,859 | 68.9K | -5% | -$5,364 |
| I | 2025-01-03 | 2024-12-31 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $1.21 | +5,000 | 142.6K | +4% | +$6,050 |
| I | 2025-01-02 | 2024-12-30 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $1.20 | +10.0K | 137.6K | +8% | +$12.0K |
| M | 2024-12-26 | 2024-12-20+ | PRLD | Combs Andrew | Chief Chemistry Off | P - Purchase | $1.36 | +63.1K | 377.6K | +20% | +$85.7K |
| 2024-12-20 | 2024-12-19 | PRLD | Lim Bryant David | CLO, Interim CFO, Corp Sec | P - Purchase | $0.91 | +25.0K | 27.4K | +1,042% | +$22.8K | |
| 2024-12-20 | 2024-12-18 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.93 | +100.0K | 1.17M | +9% | +$93.0K | |
| I | 2024-12-20 | 2024-12-19 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.89 | +6,888 | 127.6K | +6% | +$6,130 |
| D | 2024-10-07 | 2024-10-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $2.00 | -3,349 | 63.3K | -5% | -$6,698 |
| D | 2024-10-07 | 2024-10-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 66.7K | +16% | — |
| D | 2024-07-08 | 2024-07-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 60.7K | +18% | — |
| D | 2024-07-08 | 2024-07-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $3.60 | -3,347 | 57.3K | -6% | -$12.0K |
| D | 2024-04-08 | 2024-04-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 54.6K | +21% | — |
| D | 2024-04-08 | 2024-04-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $4.74 | -3,347 | 51.3K | -6% | -$15.9K |
| D | 2024-01-08 | 2024-01-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 49.1K | +24% | — |
| D | 2024-01-08 | 2024-01-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $3.77 | -3,844 | 45.3K | -8% | -$14.5K |
| D | 2023-10-06 | 2023-10-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 39.7K | +31% | — |
| D | 2023-07-06 | 2023-07-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 33.6K | +39% | — |
| D | 2023-07-06 | 2023-07-04 | PRLD | Huang Jane | Pres, CMO | F - Tax | $4.65 | -3,242 | 30.4K | -10% | -$15.1K |
| M | 2023-05-26 | 2023-05-24+ | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $5.15 | +1,900 | 1.07M | +0.2% | +$9,789 |
| 2023-05-25 | 2023-05-23 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $5.63 | +11.9K | 1.07M | +1% | +$66.7K | |
| 2023-05-25 | 2023-05-24 | PRLD | Lim Bryant David | CLO, Corp Sec | P - Purchase | $5.39 | +2,400 | 2,400 | New | +$12.9K | |
| 2023-05-25 | 2023-05-23 | PRLD | Chardonnet Laurent | CFO | P - Purchase | $5.50 | +5,000 | 42.2K | +13% | +$27.5K | |
| I | 2023-05-24 | 2023-05-22 | PRLD | Bonita David P | Dir, 10% | P - Purchase | $5.75 | +869.6K | 10.12M | +9% | +$5.00M |
| I | 2023-05-24 | 2023-05-22 | PRLD | ORBIMED CAPITAL LLC | Dir, 10% | P - Purchase | $5.75 | +869.6K | 10.12M | +9% | +$5.00M |
| D | 2023-04-06 | 2023-04-06 | PRLD | Huang Jane | Pres, CMO | S - Sale+OE | $6.12 | -13.3K | 24.2K | -35% | -$81.3K |
| D | 2023-04-06 | 2023-04-04 | PRLD | Huang Jane | Pres, CMO | M - OptEx | — | +37.5K | 37.5K | New | — |
| I | 2022-12-21 | 2022-12-20 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $5.13 | +19.2K | 120.7K | +19% | +$98.4K |
| 2022-12-12 | 2022-12-08 | PRLD | Chardonnet Laurent | CFO | P - Purchase | $4.76 | +10.0K | 35.9K | +39% | +$47.6K | |
| 2022-06-01 | 2022-06-01 | PRLD | Chardonnet Laurent | CFO | P - Purchase | $4.23 | +10.0K | 24.5K | +69% | +$42.3K | |
| D | 2022-04-04 | 2022-03-31 | PRLD | Combs Andrew | EVP, Head of Chemistry | M - OptEx | $1.89 | +36.1K | 304.4K | +13% | +$68.2K |
| 2022-03-22 | 2022-03-21 | PRLD | Chardonnet Laurent | CFO | A - Grant | $7.51 | +6,500 | 14.5K | +81% | +$48.8K | |
| DM | 2021-12-17 | 2021-12-15 | PRLD | Morosini Deborah | EVP, Chief of Clinical Affairs | M - OptEx | $11.70 | +28.8K | 3,460 | New | +$336.4K |
| D | 2021-12-17 | 2021-12-15 | PRLD | Morosini Deborah | EVP, Chief of Clinical Affairs | S - Sale+OE | $13.00 | -28.8K | 444 | -98% | -$373.8K |
| M | 2021-12-15 | 2021-12-13+ | PRLD | Combs Andrew | EVP, Head of Chemistry | P - Purchase | $11.86 | +8,000 | 268.4K | +3% | +$94.9K |
| 2021-12-14 | 2021-12-13 | PRLD | Chardonnet Laurent | CFO | A - Grant | $12.28 | +5,000 | 8,000 | +167% | +$61.4K | |
| 2021-12-14 | 2021-12-13 | PRLD | Vaddi Krishna | Pres, CEO, Dir | A - Grant | $12.13 | +8,000 | 1.05M | +0.8% | +$97.0K | |
| DM | 2021-11-18 | 2021-11-16 | PRLD | Morosini Deborah | EVP, Chief of Clinical Affairs | S - Sale+OE | $15.88 | -28.8K | 844 | -97% | -$456.5K |
| D | 2021-11-18 | 2021-11-16 | PRLD | Morosini Deborah | EVP, Chief of Clinical Affairs | M - OptEx | $12.85 | +28.8K | 29.2K | +6,475% | +$369.5K |
| DM | 2021-10-06 | 2021-10-05 | PRLD | Mauro David J | Chief Medical Off | S - Sale+OE | $30.96 | -15.0K | 9,092 | -62% | -$464.3K |
| D | 2021-10-06 | 2021-10-05 | PRLD | Mauro David J | Chief Medical Off | M - OptEx | $1.89 | +15.0K | 15.0K | New | +$28.4K |
| DM | 2021-09-09 | 2021-09-07 | PRLD | Mauro David J | Chief Medical Off | S - Sale+OE | $36.68 | -15.0K | 0 | -100% | -$550.3K |
| D | 2021-09-09 | 2021-09-07 | PRLD | Mauro David J | Chief Medical Off | M - OptEx | $1.89 | +15.0K | 15.0K | New | +$28.4K |
| DM | 2021-09-07 | 2021-09-02 | PRLD | Pierce Christopher | EVP, Chief of Business Oper | S - Sale+OE | $41.68 | -17.0K | 3,750 | -82% | -$708.5K |
| D | 2021-09-07 | 2021-09-02 | PRLD | Pierce Christopher | EVP, Chief of Business Oper | M - OptEx | $12.85 | +17.0K | 20.8K | +453% | +$218.4K |
| DM | 2021-08-30 | 2021-08-26+ | PRLD | Scherle Peggy | CSO | S - Sale+OE | $35.75 | -7,714 | 173.5K | -4% | -$275.8K |
| DM | 2021-08-30 | 2021-08-26+ | PRLD | Scherle Peggy | CSO | M - OptEx | $1.43 | +7,714 | 178.9K | +5% | +$11.0K |
| DM | 2021-08-27 | 2021-08-25 | PRLD | Piper Brian | CFO | S - Sale+OE | $33.34 | -8,333 | 2,344 | -78% | -$277.8K |
| D | 2021-08-27 | 2021-08-25 | PRLD | Piper Brian | CFO | M - OptEx | $1.89 | +8,333 | 8,333 | New | +$15.7K |
| DM | 2021-08-17 | 2021-08-13 | PRLD | Scherle Peggy | CSO | M - OptEx | $1.54 | +2,286 | 173.5K | +1% | +$3,526 |
| D | 2021-08-17 | 2021-08-13 | PRLD | Scherle Peggy | CSO | S - Sale+OE | $35.07 | -2,286 | 172.9K | -1% | -$80.2K |
| D | 2021-08-09 | 2021-08-05 | PRLD | Mauro David J | Chief Medical Off | M - OptEx | $1.89 | +15.0K | 15.0K | New | +$28.4K |
| DM | 2021-08-09 | 2021-08-05 | PRLD | Mauro David J | Chief Medical Off | S - Sale+OE | $31.09 | -15.0K | 6,821 | -69% | -$466.4K |
| DM | 2021-07-29 | 2021-07-27 | PRLD | Scherle Peggy | CSO | S - Sale+OE | $35.47 | -20.0K | 172.9K | -10% | -$709.4K |
| D | 2021-07-29 | 2021-07-27 | PRLD | Scherle Peggy | CSO | M - OptEx | $1.43 | +20.0K | 192.9K | +12% | +$28.6K |
| DM | 2021-07-08 | 2021-07-06 | PRLD | Mauro David J | Chief Medical Off | S - Sale+OE | $27.48 | -15.0K | 4,555 | -77% | -$412.1K |
| D | 2021-07-08 | 2021-07-06 | PRLD | Mauro David J | Chief Medical Off | M - OptEx | $1.89 | +15.0K | 15.0K | New | +$28.4K |